- Name: Ran-Yi Liu
- Title: Professor
- Email: liury@sysucc.org.cn
- Phone:
Dr Liu is a professor of oncology and molecular medicine in Sun Yat-sen University Cancer Center. His group mainly focused on the researches in targeted therapy of malignant tumors, which have been supported by grants from the National High Technology Research and Development Program of China (1 project), the National Natural Science Foundation of China (4 projects), and other government foundations. He has published 70 research papers in the SCI jounals. The research achievements in his group on cancer gene therapy received the first prize in Natural Science Award of Ministry of Education and the first prize in Science & Technology Progress Award of Guangdong Province. An anti-angiogenic gene medicine developed in his group has almost finished its phase III clinical trial.
Postdoctoral fellowship, Indiana University School of Medicine, IN 46202, USA 2008-2009 (focused on: anticancer drug resistance/sensitivity)
Doctor of Philosophy, Sun Yat-sen University, China 2003-2007 (Major: Experimental Oncology)
Master of Medicine, Tongji Medical University, China 1995-1998 (Major: Biochemistry & Molecular Biology)
Bachelor of Science, Nanjing University, China 1985-1989 (Major: Biochemistry)
Ten Selected publications: (* corresponding authors; # co-first author)
1. Pharmacological inhibition of BAP1 recruits HERC2 to competitively dissociate BRCA1-BARD1, suppresses DNA repair and sensitizes CRC to radiotherapy. Yue X, Liu T, Wang X, Wu W, Wen G, Yi Y, Wu J, Wang Z, W, Wu R, Meng Y, Cao Z, Le L, Qiu W, Zhang X, Li Z, Chen Y, Wan G, Bu X*, Peng Z*, Liu RY*. Acta Pharmaceutica Sinica B 2023
2. Disulfiram enhances cisplatin cytotoxicity by forming a novel platinum chelate Pt(DDTC)3. Yuan XX, Duan YF, Luo C, Li L, Yang MJ, Liu TY, Cao ZR, Huang W, Bu X, Yue X*, Liu RY*. Biochem Pharmacol 2023
3. CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer. Peng QH, Wang CH, Chen HM, Zhang RX, Pan ZZ, Lu ZH, Wang GY, Yue X, Huang W, Liu RY*. J Immunother Cancer 2021
4. Up-regulation of indoleamine 2,3-dioxygenase 1 (IDO1) expression and catalytic activity is associated with immunosuppression and poor prognosis in penile squamous cell carcinoma patients. Zhou QH, Han H*, Lu JB, Liu TY, Huang KB, Deng CZ, Li ZS, Chen JP, Yao K, Qin ZK, Liu ZW, Li YH, Guo SJ, Ye YL, Zhou FJ, Liu RY*. Cancer Commun (Lond). 2020
5. HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma. Zhou QH, Li KW, Chen X, He HX, Peng SM, Peng SR, Wang Q, Li ZA, Tao YR, Cai WL, Liu RY*, Huang H*. J Immunother Cancer. 2020
6. Genome-wide RNAi screening identifies RFC4 as a factor that mediates radioresistance in colorectal cancer by facilitating non-homologous end joining repair. Wang XC, Yue X*, Zhang RX, Liu TY, Pan ZZ, Yang MJ, Lu ZH, Wang ZY, Peng JH, Le LY, Wang GY, Peng QH, Meng Y, Huang W*, Liu RY*. Clin Cancer Res. 2019
7. The Heterogeneity Between Lynch-Associated and Sporadic MMR Deficiency in Colorectal Cancers. Liu GC#, Liu RY#, Yan JP#, An X#, Jiang W, Ling YH, Chen JW, Bei JX, Zuo XY, Cai MY, Liu ZX, Zuo ZX, Liu JH, Pan ZZ, Ding PR. J Natl Cancer Inst. 2018
8. Molecular characterization and integrative genomic analysis of a panel of newly established penile cancer cell lines. Zhou QH, Deng CZ, Li ZS, Chen JP, Yao K, Huang KB, Liu TY, Liu ZW, Qin ZK, Zhou FJ, Huang W, Han H*, Liu RY*. Cell Death Dis. 2018
9. BST2 confers cisplatin resistance via NF-κB signaling in nasopharyngeal cancer. Kuang CM, Fu X, Hua YJ, Shuai WD, Ye ZH, Li Y, Peng QH, Li YZ, Chen S, Qian CN, Huang W*, Liu RY*. Cell Death Dis. 2017
10. Role of eIF3a in regulating cisplatin sensitivity and in translational control of nucleotide excision repair of nasopharyngeal carcinoma. Liu RY#, Dong Z#, Liu J, Yin JY, Zhou L, Wu X, Yang Y, Mo W, Huang W, Khoo SK, Chen J, Petillo D, Teh BT, Qian CN, Zhang JT. Oncogene 2011